CompletedNCT00938301
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
Medication studyAges 18–55United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00938301
- Official title
Show the full official title
A Phase 1, Placebo-Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects
Get this study by email
Recruitment & locations
CompletedNew Haven
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including PF-04455242 and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
